| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/20000 | Human,Mouse,Rat |
| Aliases | CGAT, VAT1, VMAT1 |
| WB Predicted band size | 56 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SLC18A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC18A1抗体的3篇参考文献示例(内容为模拟示例，仅供参考)：
1. **《SLC18A1 expression in neuroendocrine tumors: a comparative study》**
- 作者：Henry, J.P. 等(2020年)
- 摘要：该研究通过Western blot和免疫组化技术，分析SLC18A1抗体在神经内分泌肿瘤组织中的表达水平，发现其高表达与肿瘤活性相关，提示其作为潜在生物标志物的可能性。
2. **《Development and validation of a specific SLC18A1 antibody for immunohistochemical applications》**
- 作者：Garcia, R.L. 等(2019年)
- 摘要：研究团队开发并验证了一种高特异性的SLC18A1抗体，通过免疫荧光和流式细胞术确认其在多种哺乳动物细胞系中的定位，为研究囊泡单胺转运机制提供工具。
3. **《Altered SLC18A1 protein levels in schizophrenia: post-mortem brain analysis》**
- 作者：Tanaka, M. 等(2015年)
- 摘要：利用SLC18A1抗体对精神分裂症患者死后脑组织进行检测，发现前额叶皮层中蛋白表达显著降低，提示其与疾病病理机制的潜在关联。
(注：以上文献信息为示例性模拟，实际引用需以真实发表的论文为准。)
The solute carrier family 18 member A1 (SLC18A1), also known as vesicular monoamine transporter 1 (VMAT1), is a transmembrane protein responsible for transporting monoamines—such as serotonin, dopamine, and norepinephrine—into synaptic vesicles for storage and subsequent release. It plays a critical role in regulating neurotransmitter signaling in both the central nervous system and neuroendocrine cells. SLC18A1 is expressed in the adrenal medulla, stomach, and specific brain regions, functioning in acidic intracellular compartments to couple monoamine uptake with proton gradients.
Antibodies targeting SLC18A1 are essential tools for studying its expression, localization, and function in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate protein levels in tissue samples or cellular models. Research involving SLC18A1 antibodies has linked this transporter to neuropsychiatric disorders, including schizophrenia and depression, as well as metabolic syndromes and cancer. Genetic variations in SLC18A1 have been associated with altered stress responses and emotional regulation, highlighting its therapeutic potential. Validation of these antibodies typically includes knockout controls and cross-reactivity checks to ensure specificity, given the high homology with its isoform VMAT2 (SLC18A2). Such studies advance understanding of monoamine dysregulation mechanisms and drug development targeting vesicular transport.
×
